Cargando…

The association of circulating levels of complement-C1q TNF-related protein 5 (CTRP5) with nonalcoholic fatty liver disease and type 2 diabetes: a case–control study

BACKGROUND: It is well-established that nonalcoholic fatty liver disease (NAFLD) is associated with type 2 diabetes mellitus (T2DM). Complement-C1q TNF-related protein 5 (CTRP5) is a novel adipokine involved in the regulation of lipid and glucose metabolism. We aimed to assess plasma levels of CTRP5...

Descripción completa

Detalles Bibliográficos
Autores principales: Emamgholipour, Solaleh, Moradi, Nariman, Beigy, Maani, Shabani, Parisa, Fadaei, Reza, Poustchi, Hossein, Doosti, Mahmood
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4660841/
https://www.ncbi.nlm.nih.gov/pubmed/26613006
http://dx.doi.org/10.1186/s13098-015-0099-z
_version_ 1782402885879857152
author Emamgholipour, Solaleh
Moradi, Nariman
Beigy, Maani
Shabani, Parisa
Fadaei, Reza
Poustchi, Hossein
Doosti, Mahmood
author_facet Emamgholipour, Solaleh
Moradi, Nariman
Beigy, Maani
Shabani, Parisa
Fadaei, Reza
Poustchi, Hossein
Doosti, Mahmood
author_sort Emamgholipour, Solaleh
collection PubMed
description BACKGROUND: It is well-established that nonalcoholic fatty liver disease (NAFLD) is associated with type 2 diabetes mellitus (T2DM). Complement-C1q TNF-related protein 5 (CTRP5) is a novel adipokine involved in the regulation of lipid and glucose metabolism. We aimed to assess plasma levels of CTRP5 in patients with NAFLD (n = 22), T2DM (n = 22) and NAFLD with T2DM (NAFLD + T2DM) (n = 22) in comparison with healthy subjects (n = 21) and also to study the association between CTRP5 levels and NAFLD and diabetes-related parameters. METHODS: All subjects underwent anthropometric assessment, biochemical evaluation and liver stiffness (LS) measurement. Insulin resistance (IR) was determined by the homeostasis model assessment (HOMA). Plasma CTRP5 levels were measured by enzyme-linked immunosorbent assay. RESULTS: We found significantly lower plasma levels of CTRP5 in patients with NAFLD + T2DM, NAFLD and T2DM (122.52 ± 1.92, 124.7 ± 1.82 and 118.31 ± 1.99 ng/ml, respectively) in comparison with controls (164.96 ± 2.95 ng/ml). In the whole study population, there was a significant negative correlations between CTRP5 and body mass index (r = −0.337; p = 0.002), fasting blood glucose (FBG) (r = −0.488; p < 0.001), triglyceride (TG) (r = −0.245; p = 0.031), HOMA-IR (r = −0.492; p < 0.001), insulin(r = −0.338; p = 0.002), LS (r = −0.544; p < 0.001), alanine aminotransferase (ALT) (r = −0.251; p = 0.027), waist-to-hip ratio (WHR) (r = −0.352; p = 0.002) and waist circumference (WC) (r = −0.357; p = 0.001). After adjustment for BMI, decrease in circulating levels of CTRP5 remained as a significant risk factor for NAFLD, T2DM and NAFLD + T2DM. The receiver operating characteristic (ROC) curves of circulating CTRP5 in predicting NAFLD and T2DM demonstrated an area under the curve (AUC) of 0.763 in T2DM, and 0.659 in NAFLD + T2DM. CONCLUSIONS: It appears that the decreased levels of CTRP5 contribute to the increased risk of T2DM and NAFLD. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13098-015-0099-z) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4660841
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46608412015-11-27 The association of circulating levels of complement-C1q TNF-related protein 5 (CTRP5) with nonalcoholic fatty liver disease and type 2 diabetes: a case–control study Emamgholipour, Solaleh Moradi, Nariman Beigy, Maani Shabani, Parisa Fadaei, Reza Poustchi, Hossein Doosti, Mahmood Diabetol Metab Syndr Research BACKGROUND: It is well-established that nonalcoholic fatty liver disease (NAFLD) is associated with type 2 diabetes mellitus (T2DM). Complement-C1q TNF-related protein 5 (CTRP5) is a novel adipokine involved in the regulation of lipid and glucose metabolism. We aimed to assess plasma levels of CTRP5 in patients with NAFLD (n = 22), T2DM (n = 22) and NAFLD with T2DM (NAFLD + T2DM) (n = 22) in comparison with healthy subjects (n = 21) and also to study the association between CTRP5 levels and NAFLD and diabetes-related parameters. METHODS: All subjects underwent anthropometric assessment, biochemical evaluation and liver stiffness (LS) measurement. Insulin resistance (IR) was determined by the homeostasis model assessment (HOMA). Plasma CTRP5 levels were measured by enzyme-linked immunosorbent assay. RESULTS: We found significantly lower plasma levels of CTRP5 in patients with NAFLD + T2DM, NAFLD and T2DM (122.52 ± 1.92, 124.7 ± 1.82 and 118.31 ± 1.99 ng/ml, respectively) in comparison with controls (164.96 ± 2.95 ng/ml). In the whole study population, there was a significant negative correlations between CTRP5 and body mass index (r = −0.337; p = 0.002), fasting blood glucose (FBG) (r = −0.488; p < 0.001), triglyceride (TG) (r = −0.245; p = 0.031), HOMA-IR (r = −0.492; p < 0.001), insulin(r = −0.338; p = 0.002), LS (r = −0.544; p < 0.001), alanine aminotransferase (ALT) (r = −0.251; p = 0.027), waist-to-hip ratio (WHR) (r = −0.352; p = 0.002) and waist circumference (WC) (r = −0.357; p = 0.001). After adjustment for BMI, decrease in circulating levels of CTRP5 remained as a significant risk factor for NAFLD, T2DM and NAFLD + T2DM. The receiver operating characteristic (ROC) curves of circulating CTRP5 in predicting NAFLD and T2DM demonstrated an area under the curve (AUC) of 0.763 in T2DM, and 0.659 in NAFLD + T2DM. CONCLUSIONS: It appears that the decreased levels of CTRP5 contribute to the increased risk of T2DM and NAFLD. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13098-015-0099-z) contains supplementary material, which is available to authorized users. BioMed Central 2015-11-25 /pmc/articles/PMC4660841/ /pubmed/26613006 http://dx.doi.org/10.1186/s13098-015-0099-z Text en © Emamgholipour et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Emamgholipour, Solaleh
Moradi, Nariman
Beigy, Maani
Shabani, Parisa
Fadaei, Reza
Poustchi, Hossein
Doosti, Mahmood
The association of circulating levels of complement-C1q TNF-related protein 5 (CTRP5) with nonalcoholic fatty liver disease and type 2 diabetes: a case–control study
title The association of circulating levels of complement-C1q TNF-related protein 5 (CTRP5) with nonalcoholic fatty liver disease and type 2 diabetes: a case–control study
title_full The association of circulating levels of complement-C1q TNF-related protein 5 (CTRP5) with nonalcoholic fatty liver disease and type 2 diabetes: a case–control study
title_fullStr The association of circulating levels of complement-C1q TNF-related protein 5 (CTRP5) with nonalcoholic fatty liver disease and type 2 diabetes: a case–control study
title_full_unstemmed The association of circulating levels of complement-C1q TNF-related protein 5 (CTRP5) with nonalcoholic fatty liver disease and type 2 diabetes: a case–control study
title_short The association of circulating levels of complement-C1q TNF-related protein 5 (CTRP5) with nonalcoholic fatty liver disease and type 2 diabetes: a case–control study
title_sort association of circulating levels of complement-c1q tnf-related protein 5 (ctrp5) with nonalcoholic fatty liver disease and type 2 diabetes: a case–control study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4660841/
https://www.ncbi.nlm.nih.gov/pubmed/26613006
http://dx.doi.org/10.1186/s13098-015-0099-z
work_keys_str_mv AT emamgholipoursolaleh theassociationofcirculatinglevelsofcomplementc1qtnfrelatedprotein5ctrp5withnonalcoholicfattyliverdiseaseandtype2diabetesacasecontrolstudy
AT moradinariman theassociationofcirculatinglevelsofcomplementc1qtnfrelatedprotein5ctrp5withnonalcoholicfattyliverdiseaseandtype2diabetesacasecontrolstudy
AT beigymaani theassociationofcirculatinglevelsofcomplementc1qtnfrelatedprotein5ctrp5withnonalcoholicfattyliverdiseaseandtype2diabetesacasecontrolstudy
AT shabaniparisa theassociationofcirculatinglevelsofcomplementc1qtnfrelatedprotein5ctrp5withnonalcoholicfattyliverdiseaseandtype2diabetesacasecontrolstudy
AT fadaeireza theassociationofcirculatinglevelsofcomplementc1qtnfrelatedprotein5ctrp5withnonalcoholicfattyliverdiseaseandtype2diabetesacasecontrolstudy
AT poustchihossein theassociationofcirculatinglevelsofcomplementc1qtnfrelatedprotein5ctrp5withnonalcoholicfattyliverdiseaseandtype2diabetesacasecontrolstudy
AT doostimahmood theassociationofcirculatinglevelsofcomplementc1qtnfrelatedprotein5ctrp5withnonalcoholicfattyliverdiseaseandtype2diabetesacasecontrolstudy
AT emamgholipoursolaleh associationofcirculatinglevelsofcomplementc1qtnfrelatedprotein5ctrp5withnonalcoholicfattyliverdiseaseandtype2diabetesacasecontrolstudy
AT moradinariman associationofcirculatinglevelsofcomplementc1qtnfrelatedprotein5ctrp5withnonalcoholicfattyliverdiseaseandtype2diabetesacasecontrolstudy
AT beigymaani associationofcirculatinglevelsofcomplementc1qtnfrelatedprotein5ctrp5withnonalcoholicfattyliverdiseaseandtype2diabetesacasecontrolstudy
AT shabaniparisa associationofcirculatinglevelsofcomplementc1qtnfrelatedprotein5ctrp5withnonalcoholicfattyliverdiseaseandtype2diabetesacasecontrolstudy
AT fadaeireza associationofcirculatinglevelsofcomplementc1qtnfrelatedprotein5ctrp5withnonalcoholicfattyliverdiseaseandtype2diabetesacasecontrolstudy
AT poustchihossein associationofcirculatinglevelsofcomplementc1qtnfrelatedprotein5ctrp5withnonalcoholicfattyliverdiseaseandtype2diabetesacasecontrolstudy
AT doostimahmood associationofcirculatinglevelsofcomplementc1qtnfrelatedprotein5ctrp5withnonalcoholicfattyliverdiseaseandtype2diabetesacasecontrolstudy